Why the study?
Treating and preventing VTE with traditional anticoagulants in pediatric patients presents many challenges, prompting an evaluation of the literature on pediatric NOAC trials.
Do non-vitamin K antagonist oral anticoagulants improve efficacy and safety compared to traditional anticoagulants in pediatric patients requiring VTE treatment or prophylaxis?
Do non-vitamin K antagonist oral anticoagulants improve efficacy and safety compared to traditional anticoagulants in pediatric patients requiring VTE treatment or prophylaxis?
NOACs such as rivaroxaban and dabigatran appear to be as effective and safe as traditional anticoagulants for VTE treatment and prophylaxis in pediatric patients, offering practical advantages like pediatric formulations.
Supports NOAC consideration in pediatric VTE; leaves open prophylaxis data and broader adoption pending ongoing trials.
Venous thromboembolism (VTE) in children can lead to significant morbidity and mortality. Traditionally, treatment for thrombotic events in pediatric patients has been limited mainly to unfractionated heparin, low-molecular-weight heparin (LMWH), or vitamin K antagonists. Since the first non–vitamin K antagonist oral anticoagulant (NOAC) was approved for adult use, these agents have gained popularity for a variety of indications. This is largely due to their ease of administration, favorable pharmacokinetic and pharmacodynamic profile, decreased food interactions, and decreased need for therapeutic drug monitoring. Treating and preventing VTE with traditional anticoagulants in pediatric patients presents many challenges. This systematic review evaluated the current literature regarding pediatric NOAC trials. Additionally, based on an up-to-date query of clinicaltrials.gov, we detail current ongoing and as-yet unpublished clinical trials, study outcomes, and projected completion dates. Published pediatric NOAC trials have included 1,007 total children to date and have ranged from phase 1 to 4, with “indications” including both thromboembolism prophylaxis and VTE treatment. Three recent phase 3 trials, specifically involving rivaroxaban and dabigatran, have shown the agents to be at least as effective as traditional anticoagulants for acute and/or extended VTE treatment, with low frequency of recurrent thrombosis and clinically significant bleeding rates. Additionally, specially developed and tested pediatric formulations have allowed for accurate and reliable dosing, oral administration, stable pharmacokinetics and pharmacodynamics, and fewer drug or food interactions. Ongoing trials, anticipated for completion in the next few years, will reveal important information with regard to thromboembolism prophylaxis in special pediatric subpopulations and settings.
No takes yet. Share an insight, caveat, or question.
Branstetter et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: